NEW! Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism. Enrollment is complete in the sunRIZE study, a global, Phase 3 multicenter, double-blind, randomized, placebo-controlled, parallel arm study designed to evaluate the efficacy and safety of ersodetug for the treatment of hypoglycemia in patients with congenital HI. Read the full press release at https://ir.rezolutebio.com/news/detail/356/rezolute-announces-completion-of-enrollment-in-the-phase-3-sunrize-study-of-ersodetug-in-patients-with-congenital-hyperinsulinism #hyperinsulinism #raredisease #congenitalhyperinsulinism #hypoglycemia | Hyperinsulinism | Congenital | HI | Hypoglycemia | Rare Disease (fb)

A healthy brain depends on normal blood glucose. 🩸🧠 ⚠️ Emmie's first blood glucose level was 13 mg/dL (70-100 mg/dL = normal). It is vital to check and manage blood glucose in newborns. Kelly, Emmie's mom, is joining our Glucose as a Vital Sign Campaign "so that no parent or child has to endure weeks/months of uncertainty and the risks from constant low blood sugars before getting a diagnosis. It took 3 exhausting months and 3 different hospitals to finally diagnose Emmie with HI after her birth and no one else should ever have to go through that." Join us on Hyperinsulinism Awareness Day, June 7, as we raise awareness of the preventable brain damage caused by hyperinsulinism. No baby should suffer needlessly – recognizing Glucose as a Vital Sign is crucial. Learn more about the Glucose as a Vital Sign campaign and Hyperinsulinism Awareness Day at https://congenitalhi.org/hyperinsulinism-awareness-day-june-7th/ 🔗 #HyperinsulinismAwarenessDay #GlucoseAsAVitalSign #hyperinsulinism #raredisease #congenitalhyperinsulinism #hypoglycemia #HIAwarenessDay | Hyperinsulinism | Congenital | HI | Hypoglycemia | Rare Disease (fb)